Business
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial
About this update from Nkarta, Inc.
[{"type":"text","content":"NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial recently opened dose expansion cohortsNKX019 clinical update is expected by year-end 2022NKX101 clinical update is expected in first half of 2023Presentations at SITC 2022 on enhanced anti-tumor activity of NKX019 when combined with CD20-targeted monoclonal antibodies in preclinical models, and next-generation commercial-scale NK cell manufacturing using pulsed stimulation of healthy donor source material SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2022. “The third quarter marked significant progress as we continue to treat patients across our two lead clinical programs,” said Paul J. Hastings, President and CEO of Nkarta. “We recently completed the first cycle of treatment for patients in the NKX019 monotherapy dose escalation cohort and look forward to announcing new clinical data by year-end, including data from responding patients reported in the last update. We’ve also opened enrollment in multiple dose expansion cohorts, where we intend to build on our prior experience with NKX019 in patients with autologous CAR T naïve, relapsed/refractory (r/r) LBCL, while simultaneously investigating activity in patients with LBCL who have previously received autologous CAR T. We will also explore NKX019 in combination with rituximab, regardless of prior CAR T treatment. NKX101 continues to enroll patients in monotherapy dose escalation, and we have updated the timing of NKX101 data in r/r AML to the first half of next year. We are continuing our mission to bring our allogeneic, off-the-shelf cell therapies to patients in outpatient and community oncology settings, enabling convenient multi-cycle treatment and broad access.\" Anticipated Clinical Milestones Nkarta plans to present additional clinical data from its ongoing Phase 1 clinical trial of NKX019 by year-end 2022 as part of a company-hosted announcement.Nkarta plans to present additional clinical data from its ongoing Phase 1 clinical trial of NKX101 in the first half of 2023. Nkarta updated...